FEMASYS INC filed a Form D with the Securities and Exchange Commission on 2025-11-14.
FEMASYS INC filed a Form D notice of an exempt securities offering with the SEC on November 14, 2025. The filing reports $8.03M sold. Its industry group is Biotechnology. It names Kathy Lee-Sepsick (Executive Officer, Director), Dov Elefant (Executive Officer), Charles Larsen (Director) (SEC Form D, November 14, 2025).
Is this your company?
Sell to companies like FEMASYS INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns FEMASYS INC.
Free to see. No signup.
More on the people and the money behind FEMASYS INC, from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when FEMASYS INC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when FEMASYS INC raises, hires or launches. No email unless you switch it on.
Watch FEMASYS INC →Get the full cited report on FEMASYS INC
What the filing shows about FEMASYS INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on FEMASYS INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives FEMASYS INC's address as 3950 Johns Creek Court, Suite 100, Suwanee, GA 30024.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for FEMASYS INC →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
FEMASYS INC is a registered filer with the SEC (CIK 1339005) and has filed since 2023-11-22. 4 filings are on record, the latest on 2026-08-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
FEMASYS INC's Form D of 2025-11-14 names Kathy Lee-Sepsick, Dov Elefant, Charles Larsen and 3 more as its officers, directors or promoters.
Its new offerings report $46.33M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $8.03M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Kathy Lee-Sepsick is named as Executive Officer and Director on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
Dov Elefant is named as Executive Officer on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
Charles Larsen is named as Director on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
Alistair Milnes is named as Director on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
Joshua Silverman is named as Director on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
Edward Uzialko is named as Director on the Form D that FEMASYS INC filed with the SEC on 14 November 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-11-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about FEMASYS INC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on FEMASYS INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FEMASYS INC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist FEMASYS INCYou get an alert in MentionFox the next time this company shows up.
If you're behind FEMASYS INC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for FEMASYS INC. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/femasys-inc-form-d-25000001